The Challenges of Treating Metastatic Melanoma With BRAF Inhibitor Monotherapy
Adil Daud, MD, clinical professor, medicine, dermatology, University of California, San Francisco, discusses the challenges of treating patients with metastatic melanoma with BRAF inhibitor monotherapy.
Adil Daud, MD, clinical professor, medicine, dermatology, University of California, San Francisco, discusses the challenges of treating patients with metastatic melanoma with BRAF inhibitor monotherapy.
At the Society for Melanoma Research 2013 Congress, Daud presented an overall survival update for BRF113220 part C, a phase II three-arm randomized study of dabrafenib alone versus combination of dabrafenib and trametinib in patients with BRAF V600 mutation-positive metastatic melanoma.
Read about the treatment of melanoma withcombinations and immunotherapies
Novel Approaches Focus on Limiting Toxicity in Older Patients With ALL
April 22nd 2024The major challenges for clinicians treating older patients with acute lymphoblastic leukemia surround the emergence of resistance to existing therapies and the toxicities associated with current chemotherapies.
Read More
Ornstein Advises on Starting Dose and Management of Lenvatinib in RCC
April 21st 2024During a Case-Based Roundtable® event, Moshe Ornstein, MD, MA, provided guidance on dosing and toxicity concerns in a patient treated with lenvatinib plus pembrolizumab for advanced renal cell carcinoma.
Read More
Rugo Surveys Peers on Treatment After Metastatic Relapse of HR+, HER2– Breast Cancer
April 20th 2024During a Case-Based Roundtable® event, Hope S. Rugo, MD, FASCO, moderated a discussion on treatment options for a patient whose breast cancer recurred several years after adjuvant therapy.
Read More
